Search results
Showing 106 to 120 of 151 results for atrial fibrillation
We have moved Medical technologies guidance 64 to become HealthTech guidance 606. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Percutaneous radiofrequency ablation for atrial fibrillation (IPG168)
We have moved interventional procedures guidance 168 to become HealthTech guidance 110. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved interventional procedures guidance 806 to become HealthTech guidance 755. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home
Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation (IPG286)
Interventional procedures, IPG286 - Issued: January 2009 --> We have moved interventional procedures guidance 286 to become HealthTech guidance 180. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .
KardiaMobile for the ambulatory detection of atrial fibrillation (MIB232)
This advice has been updated and replaced by NICE healthtech guidance 606.
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
Atrial fibrillation: pulse rhythm assessment in people at risk (IND168)
This indicator has been withdrawn following National Screening Committee recommendations and ongoing research.
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.
Cryoablation for atrial fibrillation in association with other cardiac surgery (IPG123)
We have moved interventional procedures guidance 123 to become HealthTech guidance 74. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation (IPG427)
Interventional procedures, IPG427 - Issued: May 2012 --> We have moved interventional procedures guidance 427 to become HealthTech guidance 286. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)
We have moved Diagnostics guidance 41 to become HealthTech guidance 553. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.